Special Issue "NMDA Receptor Antagonists for Treatment of CNS Disorders"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (30 December 2012)
Prof. Dr. Adeboye Adejare
Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, 600 S. 43rd Street, Philadelphia, PA 19104, USA
Interests: drug targeting; mechanisms of neurodegeneration; chemistry of fluoroaromatic compounds; pharmaceutical profiling
Glutamate receptors are known to play key roles in the CNS. Over-activity of these receptors which may be due to several factors including over-expression and higher levels of glutamate, has been linked to several CNS disorders. Glutamate receptors can broadly be divided into metabotropic and ionotropic. The ionotropic receptors have been further sub classified into three mainly based on agonists, namely, N-methyl-D- aspartic acid (NMDA), Kaininc acid and (alpha-amino-3-hydroxy-5-methyl-4- isoxazole-propionic acid) AMPA. While all these receptors are possible drug targets, the NMDA receptor has been particularly targeted for drug discovery efforts. These efforts have led to memantine, a USA FDA approved drug for treatment of Alzheimer’s disease. Other drugs acting at NMDA receptors are being examined for various disorders, from severe depression to drug abuse, to treatment of memory and learning issues in neurofibromatosis type 1 (NF1). The goal of this special issue is to examine current efforts in CNS drug discovery through this receptor.
Prof. Dr. Adeboye Adejare
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- NMDA antagonist
- CNS drug discovery
- Alzheimer’s disease
- neuropathic pain
- drug addiction
- memory and learning
- ionotropic receptors
Pharmaceuticals 2013, 6(2), 251-268; doi:10.3390/ph6020251
Received: 30 November 2012; in revised form: 29 January 2013 / Accepted: 29 January 2013 / Published: 6 February 2013| Download PDF Full-text (304 KB) | Download XML Full-text
Article: Interactions of a Dopamine D1 Receptor Agonist with Glutamate NMDA Receptor Antagonists on the Volitional Consumption of Ethanol by the mHEP Rat
Pharmaceuticals 2013, 6(4), 469-479; doi:10.3390/ph6040469
Received: 25 December 2012; in revised form: 23 February 2013 / Accepted: 15 March 2013 / Published: 26 March 2013| Download PDF Full-text (212 KB) | Download XML Full-text
Pharmaceuticals 2013, 6(4), 480-499; doi:10.3390/ph6040480
Received: 31 January 2013; in revised form: 27 March 2013 / Accepted: 27 March 2013 / Published: 3 April 2013| Download PDF Full-text (237 KB) | Download XML Full-text
Pharmaceuticals 2013, 6(4), 536-545; doi:10.3390/ph6040536
Received: 25 January 2013; in revised form: 9 April 2013 / Accepted: 9 April 2013 / Published: 12 April 2013| Download PDF Full-text (1046 KB) | Download XML Full-text
Pharmaceuticals 2013, 6(8), 1039-1054; doi:10.3390/ph6081039
Received: 29 May 2013; in revised form: 6 August 2013 / Accepted: 19 August 2013 / Published: 21 August 2013| Download PDF Full-text (138 KB) | Download XML Full-text
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: NMDA Receptor Antagonists and Partial Agonists in the Treatment of Drug Addiction
Authors: R.J. Malcolm and M.F. Olive
Affiliation: Department of Psychology, Arizona State University, Tempe, Arizona 85287, USA; E-Mail:email@example.com
Abstract: It is now clear that glutamate plays a pivotal role in drug addiction, and the NMDA receptor serves as a molecular target for several drugs of abuse. In this review, we will summarize known direct interactions of various drugs of abuse with the NMDA receptor, as well as changes in NMDA receptor subunit expression produced by chronic drug exposure. We will also review the mechanism of action, clinical efficacy, and adverse side effects of NMDA receptor ligands that are currently used in the treatment of drug addiction. Such compounds include the NMDA receptor antagonists acamprosate and memantine, as well as the partial NMDA agonist D-cycloserine. Data collected to date suggest that direct NMDA receptor modulators have relatively limited efficacy in the treatment of drug addiction, and clinical examination of newer subunit selective NMDA receptor ligands is needed to determine if the NMDA receptor remains a viable therapeutic target for addictive disorders.
Last update: 11 September 2012